Haleon plc (NYSE:HLN) Shares Sold by Capital Fund Management S.A.

Capital Fund Management S.A. reduced its holdings in Haleon plc (NYSE:HLN) by 75.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,421 shares of the company’s stock after selling 168,779 shares during the period. Capital Fund Management S.A.’s holdings in Haleon were worth $519,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Procyon Advisors LLC grew its stake in Haleon by 41.3% in the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock valued at $2,196,000 after acquiring an additional 67,329 shares during the period. Jane Street Group LLC grew its position in shares of Haleon by 1,689.4% in the third quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock valued at $2,803,000 after purchasing an additional 250,169 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Haleon by 29.8% during the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company’s stock worth $19,758,000 after purchasing an additional 475,934 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares during the last quarter. Finally, SeaCrest Wealth Management LLC purchased a new position in Haleon in the 4th quarter valued at about $102,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Up 0.5 %

NYSE HLN opened at $10.17 on Thursday. The business’s fifty day simple moving average is $10.07 and its 200-day simple moving average is $9.81. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $45.95 billion, a PE ratio of 29.91, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a 52 week low of $8.04 and a 52 week high of $10.80.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, equities analysts anticipate that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. Haleon’s dividend payout ratio is currently 58.97%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Six analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.